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Abstract 
Background 
Novel drugs are dynamically changing current treatment regimens for multiple 
myeloma (MM). Novel drugs have improved prognosis of MM patients in clinical 
studies but are expensive. Little is known about up-to-date real-world application and 
costs. 
Methods  
We performed a retrospective observational cohort analysis (cost-outcome 
description; 2012-2017) in a claims database of a major Swiss health insurance 
company which covers 14% of the Swiss population (Helsana Versicherungen 
AG).We used primary (MM diagnoses via ICD-10) and secondary features 
(prescribed MM-specific drugs) as inclusion criteria and defined a hierarchy of drug 
regimens to classify treatments as: 1) proteasome inhibitor (PI)-based regimen (e.g. 
bortezomib); 2) IMID-based regimen (e.g. lenalidomide); 3) chemotherapy (CHEMO)-
based regimen (e.g. bendamustin); 4) monoclonal antibody (MAB)-based regimen 
(e.g. daratunumab). Direct medical costs of mandatory health insurance were 
analysed in 2017 Swiss Francs (CHF; third party payer perspective). 
Results  
Overall, we identified n=1054 prevalent MM patients (2012-2017) and n=378 incident 
MM patients (2015-2017; men: 47.1%; age group <=75 years: 48.7%). The number 
of prevalent patients per year increased over time (from n=314 in 2012 to n=645 in 
2017). 
PI-based regimens were the most frequent first line approach for incident patients 
(76.0%), followed by IMID-based (21.9%) and CHEMO-based regimens (2.1%). Only 
four patients were treated with MAB-drugs. For later lines, IMID-based regimens 
were most often used (2nd line: 56.4%; 3rd line: 2 of 3 patients), followed by PI-based 
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regimens (43.6% and 1 of 3 patients, respectively). 161 of 1054 prevalent MM 
patients (15.3%) were treated with autologous hematopoietic stem cell 
transplantation (HSCT), 4 patients with allogeneic HSCT. 
Average costs per patient per treatment line varied considerably (reliable data 
available from 2012 to 2014; mean duration of lines between 112 and 388 days): PI-
based regimens: CHF 81’352; IMID-based: CHF 73’495; CHEMO-based: CHF 683. 
Mean daily costs under MM treatment stepwise increased from CHF 209 in 2012 to 
CHF 254 in 2017 (relative increase: 21.5%). Annual direct medical costs in 
Switzerland for seven novel MM drugs were extrapolated to be 60.1 Mio CHF in 2012 
and 118.6 Mio CHF in 2017 (relative increase: 97.3%), corresponding to mean 
annual outpatient MM drug costs per patient of CHF 28’000 in 2017. 
Annual death rates decreased systematically from 18.6% in 2012 to 15.5% in 2017 (p 
for trend: 0.03). No statistically significant difference in death rates emerged for 2017 
compared with 2012 (risk ratio: 0.83; 95%-CI: 0.63 to 1.10; absolute risk reduction: 
3.1%). 
Conclusions 
Current treatment patterns for MM patients in Switzerland show variation concerning 
applied drug regimens as well as costs. An increasing prevalent population of MM 
patients in combination with increasing costs per day under treatment lead to a 
substantial and growing budget impact for the Swiss social insurance system. 
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Background 
Multiple myeloma (MM) is the second most frequent hematologic malignancy in 
Switzerland. Incidence of MM is increasing since 1990 world-wide [1] and it presents 
a considerable burden to patients and the health care system. [2] Novel drugs (e.g. 
bortezomib, lenalidomide, carfilzomib) have considerably changed current treatment 
regimens for MM. Novel approaches have also improved prognosis of MM patients 
but are expensive. [2-4] Updated guidelines for Switzerland [2] and for Europe [3] 
advise clinicians regarding the translation of current evidence derived from clinical 
studies into treatment strategies in clinical practice to secure patient benefit. 
Little is known, however, regarding the use of current MM treatment regimens in 
routine clinical practice, associated costs and mortality in the real-world setting. [5, 6] 
For Switzerland, data exist only from a pan-European study with very few Swiss 
patients included. [7, 8] 
Health care claims data cover a large population and are increasingly used in health 
services research. They are usually reliable as they underly multiple check 
procedures and represent a well-established approach to collect and analyse real-
world treatment data and costs. Such data allow quantifying the medical and 
economic burden of a disease to better understand current public health challenges 
and to optimise resource allocation. We therefore used health care claim-based data 
to describe the current real-world patterns and associated costs of MM treatment in 
Switzerland.  
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Methods 
 
Study design 
We performed a retrospective, observational study (cost-outcome description [9]). 
We used the claims database of consecutive cases of a major national Swiss health 
insurance company, which covers about 14% of the Swiss population (Helsana 
Versicherungen AG).  
According to the Human Research Act in Switzerland, approval from a local Ethics 
committee was not required for studies using an anonymised database. The study 
was partly funded by Amgen Switzerland. The funding party had no influence on the 
concept of the study, data collection, analysis or interpretation of results. 
 
Study period and patients 
Data were collected from the complete calendar years 2012 to 2017. To be included, 
cases had to be insured with Helsana health insurance for the complete calendar 
year (prevalence view). In addition, complete three preceding years without 
identification of MM were required to allow the inclusion as incident cases (incidence 
view). In case of death, cases were included even if their Helsana health insurance 
coverage was less than 12 months in that year.Thus, prevalent cases relate to the 
years 2012 to 2017 , incident cases to the years 2015 to 2017 (Supplement: Figure 
S1). For analyses of treatment lines and costs, we relied on the incident population, 
because in this population we could unequivocally identify the first and subsequent 
treatment lines of each given case. 
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Inclusion criteria 
The used health insurance database holds no direct information concerning the 
diagnosis of their patients treated in the outpatient sector. Thus, we had to rely on an 
algorithm using primary and secondary inclusion criteria for MM. For patients with in-
hospital treatment we used ICD10 diagnosis codes as primary identification (C90.0 
Multiple myeloma). 
For patients without hospitalisation and without the respective ICD code hospital 
discharge codes for identification of MM, we applied a filter algorithm for specific 
drugs to select patients suffering from MM with a very high probability (secondary 
inclusion criteria). Approved and reimbursed MM drugs in Switzerland (bortezomib, 
carfilzomib, ixazomib, lenaladomide, pomalidomide, elotuzumab, daratumumab) 
were identified via ATC-codes, as well as other drugs mostly used in the context of 
MM treatment (e.g. Bendamustin; Melphalan; Dexamathasone; Zoledronate). Of 
these identified cases, we excluded those with additional use of Rituximab (as an 
indicator for non-Hodgkin lymphoma), and with the use of iron chelators (e.g. 
desferoxamine, as an indicator for Myelodysplastic Syndrome). 
 
Information from claims database 
Data were collected for the study population (per person per year) for demographic 
attributes (e.g. age, gender, death [yes/no]), health insurance attributes (e.g. 
managed care coverage [yes/no]), sequence of MM medications to identify treatment 
regimens, hematopoietic stem cell transplantation (HSCT: Swiss-DRG codes: A15C 
autologous; A04C allogeneic) and in-hospital stay due to MM. 
Validated death data of the years 2012 and 2013 were taken from an earlier pilot 
study. This was necessary as a recoding for some variables in the insurance 
database took place during the observation period. Thus, prevalence figures used as 
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denominators for calculation of death rates in 2012 and 2013 are not identical with 
prevalence figures reported in our study for other outcomes than death. 
 
Treatment patterns 
We grouped MM treatments according to the major drug backbone into drug 
regimens (Table S1): The PI-based regimen for the proteasome inhibitor concept 
(e.g. bortezomib), the immunomodulatory (IMID)-based regimen (e.g. lenalidomide), 
the CHEMO-(chemo therapy-) based regimen (e.g. bendamustin) and the MAB-
(monoclonal antibody)-based regimen (e.g. Elotuzumab) [10-12]. In addition, a 
hierarchy of regimens was defined (PI > IMID > CHEMO > MAB) to meaningfully 
group simultaneously prescribed MM drugs to MM regimens. For example, if 
bortezomib and lenalidomide were applied within one drug regimen, the regimen was 
defined as PI-based regimen; if lenalidomide and bendamustin were applied within 
one drug regimen, the regimen was defined as IMID-based regimen.  
As a pragmatic compromise, we defined a new treatment line as a MM treatment 
regimen after a “watch and wait phase” of at least 180 days without prescription of a 
MM specific drug (i.e. PI-; IMID-; CHEMO-; MAB-drug). As no information was 
available in the claims database about the reasons for change of treatment (e.g. due 
to relapse or side effects) or treatment breaks (e.g. due to remission), we performed 
a validation study to better understand prescription patterns of MM drugs in our 
claims database. A visual inspection of diverse MM drug patterns of 16 example 
patients showed that a shorter period than 180 days (for example, 60 days) would 
erroneously detect a “new line” also in cases where clearly no new line was visible in 
the validation patterns. Current Swiss guidelines recommend repetition of drug 
regimens after 21 days to 6 weeks within a treatment line [2] and prescription can be 
given (and, thus, claims can exist) for several cycles together. For example, one 
prescription of 5 drug packages at a time of the same MM drug may hold for 5 
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therapy cycles within the same treatment line (5 x 28 days = 140 days). 
Consequently, the next prescription of the same drug within the same treatment line 
after 140 days would mimic a new line, if the limit would be set at, for example, 60 
days and not at 180 days. 
 
Health economic analysis 
Analysis was done from the perspective of a third party payer (Helsana Insurance 
AG). In Switzerland, in-hospital drug costs are in general included in the Swiss-DRG 
tariffs and not separately reimbursed by health insurers. In the outpatient sector, 
health insurers pay each drug prescription on a fee-for-service base. 
Direct medical costs (e.g. total medication cost of MM medications listed in inclusion 
criteria) were defined from the database via number of reimbursed units (e.g. 
prescribed medication package) multiplied with current Swiss basic health insurance 
tariffs (OKP) per unit. Costs for in-hospital treatment in Switzerland are based on 
Swiss-DRG cost weights multiplied with a base rate (45% of in-hospital treatment are 
paid by the patients’ mandatory health insurance and included in our study; 55% by 
public authorities [cantons] and not included in our study). Costs are presented as 
2017 Swiss Francs (CHF; official 2017 conversion rate to Euros: 0.85). [13] Out-of-
pocket payments and deductibles of the patients were not accounted for. In addition, 
we did not apply a discount rate for costs due to the short observation period.  
The extrapolation of costs to the Swiss population was performed with Helsana 
market shares per stratum as defined in the Swiss risk compensation scheme to 
adjust for differences across demographics between the Helsana population and the 
general Swiss population. [14] The applied attributes for defining the strata were age 
group, canton of residence and gender which result in 32 groups per canton of 
residence. 
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Statistical analysis 
For our descriptive analysis, we used means (standard deviation) or medians 
(interquartile range [IQR]) for continuous variables and proportions for categorical 
data. For inferential analysis, we applied parametric and non-parametric tests and p-
values <0.05 were considered significant. R was used for data analysis: R version 
3.5.0 (2018-04-23) - R Core Team (2017). R: A language and environment for 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria.URL 
https://www.R-project.org/.  
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Results 
Patient population 
We identified n=1054 prevalent MM patients (2012-2017) with 3061 person-years 
under observation, and n=378 incident MM cases (2015-2017; study flow Figure 1). 
Patient characteristics and the number of patients per year of the two groups are 
depicted in Table 1. For prevalent patients, the number of patients per year increased 
over time (from n=314 in 2012 to n=645 in 2017), as well as patient age (age group 
>75 years: from 38.2% to 47.1%) and managed care coverage (from 33.8% to 
49.6%). No clear pattern emerged for other variables. For example, the ratio of 
incident patients identified via ICD-code, hence with first diagnosis of MM in a 
hospital, varied between 70% and 82% from 2015 to 2017.  
When we extrapolated the figures derived from the Helsana sample to the Swiss 
population, figures for 2017 did correspond to 61.0 prevalent cases per 100’000 
inhabitants (95%-CI: 58.3 to 63.8) and 10.5 incident cases / 100’000 (95%-CI: 8.6 to 
12.5). 
 
Drug treatment patterns 
Of 378 incident patients, 292 (77.2) provided outpatient drug data with a mean follow-
up of 2.1 years between 2015 and 2017 to assess drug treatment in further detail. 
For 1st-line therapy, PI-based regimens were the most frequent approach (76.0%), 
followed by IMID-based (21.9%) and CHEMO-based regimens (2.1%; Figure 2). Only 
four patients were treated with MAB-drugs, three times as part of PI-based regimens 
and once as part of an IMID-based regimen. 
Age distribution across 1st-line therapies showed a decrease of the younger age 
population from PI-based (age group <=75 years: 59%), over IMID-based (48%) to 
CHEMO-based (17%) regimens (Table 2). 
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Mean duration of 1st-line treatment in 2015 and 2016 was between 210 and 298 days 
for PI-based regimens, between 197 and 327 days for IMID-based regimens and 
between 30 and 61 days for CHEMO-based regimens (Table S2).  
Mean time to next treatment in 2015 and 2016 (TTNT; i.e. interval from last day of 
1st-line to first day of 2nd-line treatment) was between 283 and 351 days for PI-based 
regimens, and between 216 and 389 days for IMID-based regimens. Only 5 patients 
provided data for CHEMO-based regimens (TTNT: 207 to 390 days). Duration of 
treatment and TTNT in 2017 were generally shorter, most probably due to the end of 
the study time window by December 2017. 
During the time window between 2015 and 2017 (mean follow-up: 2.1 years), 237 
(81.2%) patients remained in their 1st-line treatment. For 55 of 292 patients (18.8%) a 
2nd-line treatment was started. The most frequent 2nd-line regimen was IMID-based 
(56.4%), followed by PI-based (43.6%) and no CHEMO-based 2nd line. Three of 292 
patients (1%) were also treated with a 3rd-line regimen during our time window (2 of 3 
with IMID-based; 1 of 3 with PI-based; no CHEMO-based regimen). 
 
Hematopoietic stem cell transplantation 
From 2012 to 2015, 161 of 1054 MM patients (15.3%) were treated with autologous 
HSCT, four patients were treated with allogeneic HSCT (Table S3). All patients with 
HSCT were younger than 75 years with a balanced gender distribution as in the total 
prevalence population of 1054 MM patients. 
 
Deceased MM patients 
The proportion of deceased patients per year showed a systematically decreasing 
trend (p for trend: 0.03) during the observation time from 2012 to 2017 (Table 1): 68 
of 366 patients (18.6%) died in 2012, 73 of 358 patients (20.4%) in 2013, 89 of 506 
patients (17.6%) in 2014, 93 of 568 (16.4%) in 2015, 99 of 620 (16.0%) in 2016 and 
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100 of 645 (15.5%) in 2017. No statistically significant difference in death rates 
emerged for 2017 compared with 2012 (risk ratio: 0.83; 95%-CI: 0.63 to 1.10; 
absolute risk reduction: 3.1%; Figure 3). 
 
Treatment costs for MM 
Direct medical costs for MM specific drugs per patient per treatment regimen varied 
considerably between regimens, as well as between years (Table 3). Valid cost data 
for complete treatment lines were available from 2012 to 2014. Cost data of 
treatment lines from 2015 to 2017 are not fully reliable due probably many 
incomplete treatment lines at the end of observation period. From 2012 to 2014, 
mean costs for PI-based treatment lines varied between CHF 74’315 and CHF 
94’914 and for IMID-based lines between CHF 59’227 and CHF 85’169. Mean costs 
for CHEMO-based regimens were considerably less costly (CHF 285 to CHF 1235). 
Mean costs per patient per day under a MM drug regimen were available from 2012 
to 2017 (formula: average costs per regimen / average number of days under a 
regimen; watch and wait periods without MM drugs are not included herein). Mean 
daily costs stepwise increased from CHF 209 in 2012 to CHF 254 in 2017 (relative 
increase: 21.5%). 
Inpatient costs of patients with autologous HSCT in the year of transplantation show 
some variability from 2012 to 2017 (range: CHF 24’597 - CHF 33’090; mean inpatient 
all diagnosis costs per patient per year; Table S3). 
We extrapolated annual outpatient MM drug costs to the general population of 
Switzerland (Table 4). Annual direct medical costs in Switzerland for seven novel 
approved and reimbursed MM drugs (bortezomib [Velcade®], lenalidomide 
[Revlimid®], pomalidomide [Imnovid®], carfilzomib [Cyprolis ®], elotuzumab 
[Empliciti ®], daratumumab [Darzalex ®], ixazomib [Ninlaro ®]) were extrapolated to 
be 60.1 Mio CHF in 2012 and 118.6 Mio CHF in 2017 (relative increase: 97.3%). In 
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2017, the relative share of costs in Switzerland among the four most frequently used 
novel agents was 55.3% for lenalidomide, 18.8% for bortezomib, 11.3% for 
pomalidomide and 7.1% for carfilzomib. 
This corresponds to mean annual outpatient MM drug costs per patient of CHF 
28’242 in 2017 (watch and wait periods without MM drugs are included herein; Table 
4). In the period 2012 to 2017, annual costs of outpatient MM drugs (mean: CHF 
26’224) accounted for about 45% of total annual costs of all-diagnoses inpatient and 
outpatient services of myeloma patients (mean: CHF 58’401), as reimbursed by 
health insurers based on the Swiss Federal Law on Basic Health Insurance 
(KVG/LAMal). 
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Discussion 
In our observational study of a claims database we analysed real-world treatment 
data of unselected MM patients in Switzerland in the era of novel MM drugs. PI-
based regimens were the by far most frequent 1st-line therapy, followed by IMID-
based and CHEMO-based regimens. Duration of 1st-line treatment in 2015 and 2016 
was between 210 and 298 days for PI-based regimens, between 197 and 327 days 
for IMID-based regimens and between 30 and 61 days for CHEMO-based regimens. 
Time to next treatment (TTNT; i.e. interval from last day of 1st-line to first day of 2nd-
line treatment) in 2015 and 2016 was between 283 and 351 days for PI-based 
regimens, and between 216 and 389 days for IMID-based regimens. For 2nd and 3rd-
line regimens IMID-based regimens are more frequent compared to PI-based 
regimens. 15.3 % of patients were treated with autologous ASCT. 
Outpatient costs for MM drugs were highest for PI-based regimens (average costs for 
treatment lines started between 2012 and 2014: CHF 81’352), followed by IMID-
based regimens (CHF 73’495). Costs for CHEMO-based regimens were much lower 
(CHF: 683), but patients treated with such regimens represent a specific group (only 
six patients in our data set with five of them in the age group >75 years). 
Extrapolated costs of novel MM drugs to the Swiss national level increased by 97% 
from 2012 to 2017. Annual mortality rates of MM patients in the prevalent population 
of this sample of a Swiss health insurance from 2012 to 2017 decreased slightly from 
18.6% to 15.5% (risk ratio: 0.83; 95%-CI: 0.63 to 1.10). 
 
Strengths and limitations 
We applied real-world data of a major Swiss health insurance that provided treatment 
information about unselected MM patients from all parts of the country. The database 
has been used in several health services research studies in different clinical 
domains. [15-17] 
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Our study has, however, several limitations. First, we were not able to use clinical 
charts of single patients to verify diagnosis, provide information about staging or 
analyse MM drug treatment and new treatment lines directly from chart reviews in 
detail (e.g. to study separation of induction and maintenance therapy or reasons for 
ending treatment). Thus, we were only able to include MM patients who had ever 
received MM drug treatment or have been treated for MM in a hospital. However, our 
filter criteria were developed in cooperation with clinical experts and the chosen filter 
variables also used ICD-coded diagnoses of inpatient treatments. For definition of a 
new treatment line we used a pause of drug prescription of 180 days as a pragmatic 
approach in the light of Swiss guidance for MM treatment [2] and the reported real-
world drug prescription modes by our clinical experts. Second, the chosen definition 
of three calendar years free of a MM drug prescription or an in-hospital stay without 
MM diagnosis for incident cases may still have been too short. Thus, we cannot 
exclude a misclassification of some prevalent cases as incident cases but this may 
be a rare event. Third, we do not recommend using the extrapolated MM prevalence 
and incidence figures for epidemiological questions. Our extrapolated estimates are 
likely to be too high as compared with published data that were properly adjusted for 
European standard populations. Fourth, we did not have direct information about co-
morbidities of patients. However, using the validated ATC-codes for medically treated 
co-morbidities, [15] we have evidence, that the co-morbidity profile of outpatients 
remained basically similar over the observation period. Fifth, some results may not 
be reliable due to a short observation time window for patients who entered the study 
late. For example, for the analysis of the sequence of treatment lines, study 
population with suitable data is decreasing rapidly from line to line. Furthermore, 
TTNT may be underestimated for patients who entered the sample in 2017 due to the 
relatively short time window until end of observation period. Finally, the Helsana 
population is somewhat older than the Swiss general population and not all parts of 
Switzerland were equally represented in our study. However, extrapolating the costs 
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to the country level we accounted for age differences, canton of residence and 
gender. 
 
Recent publications with real-world data of MM patients 
We compared our findings with recently published real-world treatment data of MM 
patients. An observational study from 6 countries [7, 8] included also data from one 
Swiss hemato-oncological centre: These cross-country findings are, however, difficult 
to compare with our results, as the European authors performed chart reviews of 
patients seen during consultation and could, thus, provide detailed clinical 
information but no figures about mortality rates and costs.  
In the multi-country study [7], the rate of patients receiving a 2nd-line (61%) and a 3rd-
line therapy (38%) is higher compared with the findings in our incident population 
(2nd-line: 19%; 3rd-line therapy: 1%). This may be partly explained with the longer 
time since diagnosis (median: 33 months) in the multi-national sample. [7] In addition, 
stem cell transplantation is less frequent in our sample (15% vs. 31%). Treatment 
patterns are similar with the most frequent 1st-line drug bortezomib (EU: 48%; PI-
based regimen in our analysis: 76%). Lenalidomid is the most frequent drug for 2nd-
line (EU: 59%; IMID-based regimen in our analysis 56%) and 3rd-line therapy (EU: 
63%; our findings: 67%. [7] A real world study from the US with data from 2006 to 
2014 found a similar pattern. [6] Treatment free intervals between lines (TTNT) in the 
EU study are between 10 months (median; after 1st line) and 5 months (after 2nd line). 
[8] We found a mean TTNT after 1st-line between 7 and 13 months, for IMID- and PI-
based regimens in 2015 and 2016). 
A real-world study from the Netherlands assessed treatment costs in MM patients. [5] 
Even though this study assessed costs between 2001 and 2009, acquisition costs for 
novel MM agents accounted for about one third of total monthly inpatient and 
outpatient costs in the Netherlands at that time. We did not calculate total health care 
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costs per patients of our sample, as we were mainly interested in diagnosis specific 
costs of MM treatment. However, it is likely that the increase in costs in our study for 
novel MM drugs in Switzerland from 2012 to 2017 accounts for more than one third 
of treatment costs in our MM patients. 
HSCT was performed in 15.3% of prevalent patients in our study. This is a similar 
fraction as in other real-world populations from the US [6] (data from 2006 to 2014: 
16.2%) or from the Netherlands [5] (data from 2001 to 2009: 20%). The European 
multi-country study [7] showed a higher fraction of HSCT (data from 2014: 31%), 
which may be due to an over-representation of patients from University oncology 
centers. 
 
Implications for clinicians and public health decision makers 
Our study provides evidence, that initial drug treatment regimens show little variability 
in accordance with current guidance. [2] However, variability of treatment patterns is 
increasing for 2nd- and 3rd-line therapy in our real-world data. Unexpected toxicities or 
patient preferences may contribute to such modifications. 
Our study shows a significant increase in daily drug costs for MM patients over a six 
year period, on the patient level as well as on the Swiss country level. For example, 
the introduction of new agents, such as pomalidomide or monoclonal antibodies, was 
not associated with a decrease in costs for other myeloma drugs. The doubling of 
costs for novel MM drugs on the national level (relative increase by 97% from 2012 to 
2017), is probably mainly due a massive increase of the prevalent MM population (as 
indicated by a relative increase of MM patients from 2012 to 2017 in our data set of 
105%). This may represent the better prognosis of MM patients and may not be due 
to a rise in MM incidence, as indicated in our data set. To a lower extend, also 
increasing MM drug costs per patient per day have contributed to a higher estimated 
spending on the national level. The relative increase of 15% of MM drug costs per 
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day (CHF 209 in 2012; CHF 241 in 2016) was similar to the relative increase of 16% 
in overall health care expenditures in Switzerland during the period 2012 to 2016 [no 
official data for 2017 available, yet]). [18] 
Surprisingly, the application of novel MM drugs is not (yet?) associated with a 
significant decrease in mortality among MM patients from 2012 to 2017. However, we 
found a significant trend towards reduced mortality. Admittedly, we have only little 
clinical information about the MM patients in our sample, but no reason to believe, 
that these MM patients are, beyond the slightly increased age, significantly different 
compared to a typical MM population in Switzerland. Our data are in line with the US 
SEER registry, where mortality from myeloma in the US population has been slightly 
decreasing over the years from 2010 to 2015 in the era of novel MM drugs. [19] Data 
from other hematologic diseases have shown decreased mortality rates also on the 
population level after introduction of novel drugs. As an example may serve the effect 
of imatinib on survival for patients with chronic myeloid leukemia, where death rates 
in the US in the SEER registry dropped from 0.6 per 100'000 in 2000, the year of 
introduction of imatinib, to 0.3 in 2007, where they remained since despite 
introduction of newer tyrosine kinase inhibitors. [19]  
Our data on novel MM drugs in Switzerland call for an introduction of “Coverage with 
Evidence Development” (CED) reimbursement. [20] This form of reimbursement 
provides continued access to novel MM drugs in Switzerland and might trigger the 
establishment of registries and research. Thus, a framework will be established to 
systematically assess and better understand the impact on patients’ outcome and 
costs in real-world settings. Monitoring such data on the population level is of 
outmost importance, to assess if novel MM drugs are associated with increased 
value for health care. [21] 
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Conclusions 
Current treatment patterns for MM patients in Switzerland show variation concerning 
applied drug regimens as well as costs. An increasing prevalent population of MM 
patients in combination with increasing costs per day under treatment lead to a 
substantial and growing budget impact for the Swiss social insurance system. 
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Glossary 
MM drug One defined pharmacological substance for MM 
treatment (e.g. BOR, LEN, BENDA) 
Treatment regimen Combination of several MM drugs (e.g. PI-based 
regimen, IMID-based regimen; CHEMO-based 
regimen; MAB-based regimen) 
Treatment line [22] Cycle of a single MM agent or a regimen of several 
MM drugs or regimens (e.g. given as 1st-line 
treatment; 2nd-line treatment; 3rd-line treatment) 
Treatment pattern Composition and sequence of MM treatments over 
time 
 
List of abbreviations 
BENDA, bendamustin 
BOR, bortezomib (e.g. Velcade ®) 
CHEMO, chemotherapy-based regimen 
DARA, daratunumab (e.g. Darzalex ®) 
DEXA, dexamethason 
DOXO, doxorubicin 
ELO, elotuzumab (e.g. Empliciti ®) 
HSCT, hematopoietic stem cell transplantation 
IMID, immunomodulatory-based regimen 
IXA, ixacomib (e.g. Ninlaro ®) 
LEN, lenalidomide (e.g. Revlimid ®) 
MEL, melphalan 
PI, proteasome inhibitor-based regimen 
POM, pomalidomide (e.g. Imnovid ®) 
PRED, prednisolon 
THAL, thalidomide 
VIN, vincristine 
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Table 1: Patient characteristics, mortality and indicators for co-morbidity of prevalent and incident MM patients. Analysis based on 
n=1054 patients from 2012-2017) 
 
 
 
*Death rates: Validated death data of the years 2012 and 2013 were taken from an earlier pilot study. This was necessary as a recoding for some variables in the insurance 
database took place during the observation period. Thus, prevalence figures used as denominators for calculation of death rates in 2012 and 2013 are not identical with prevalence 
figures reported in our study for other outcomes than death. 
ATC: WHO Anatomical therapeutic chemical (ATC) classification system for drugs, an indicator for co-morbidity 
PCG: pharmacy cost groups; an indicator for co-morbidity 
 
n=1054 prevalent MM patients n=378 incident patients
Jahr 2012 Jahr 2013 Jahr 2014 Jahr 2015 Jahr 2016 Jahr 2017 p trend Jahr 2015 Jahr 2016 Jahr 2017 p trend
group size n 314 408 506 568 620 645 145 125 108
age '<=75' n (%) 194 (61.8) 243 (59.6) 284 (56.1) 312 (54.9) 338 (54.5) 341 (52.9) < 0.01 69 (47.6) 62 (49.6) 53 (49.1)
age '>75' n (%) 120 (38.2) 165 (40.4) 222 (43.9) 256 (45.1) 282 (45.5) 304 (47.1) < 0.01 76 (52.4) 63 (50.4) 55 (50.9)
gender 'female' n (%) 159 (50.6) 208 (51) 255 (50.4) 294 (51.8) 311 (50.2) 323 (50.1) 0.57 77 (53.1) 68 (54.4) 55 (50.9)
gender 'male' n (%) 155 (49.4) 200 (49) 251 (49.6) 274 (48.2) 309 (49.8) 322 (49.9) 0.57 68 (46.9) 57 (45.6) 53 (49.1)
managed care coverage 'yes' n (%) 106 (33.8) 148 (36.3) 190 (37.5) 240 (42.3) 288 (46.5) 320 (49.6) < 0.01 66 (45.5) 58 (46.4) 59 (54.6)
deceased 'yes' n (%) 68/366 (18.6)* 73/358 (20.4)*  89 (17.6)  93 (16.4)  99 (16.0) 100 (15.5) 0.03  20 (13.8)  16 (12.8) 12 (11.1)
identification via C90 'yes' n (%) 191 (60.8) 290 (71.1) 422 (83.4) 468 (82.4) 509 (82.1) 505 (78.3) 0.11 114 (78.6) 102 (81.6) 76 (70.4)
nr. of different ATC mean (median) 22.9 (22) 22.5 (22) 21.9 (21) 21.7 (21) 22.1 (21) 21.1 (20) 0.02 26.2 (26) 27.2 (27) 25.6 (25)
nr. of PCG mean (median) 4.8 (5) 4.7 (5) 4.5 (5) 4.6 (4.5) 4.5 (4) 4.4 (4) 0.01 5.3 (5) 5.4 (5) 5.4 (5)
PI-based regimen n (%) 100/119 (84.0) 73/90 (81.1) 49/83 (59.0) 0.27
IMID-based regimen n (%) 16/119 (13.4) 15/90 (16.7) 33/83 (39.8) 0.26
CHEMO-based regimen n (%) 3/119 (2.6) 02/90 (2.2) 01/83 (1.2) 0.15
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Table 2: First line treatment patterns, patient variables, mortality and HSCT for MM patients. Analysis based on 292 of 378 incident MM 
patients with outpatient drug data from 2015-2017. 
 
HSCT: Hematopoietic stem cell transplantation 
 
 
2015-2017: Regimens PI-based IMID-based CHEMO-based TOTAL
group size N 222 76% 64 22% 6 2% 292 100%
group size n 222 100% 64 100% 6 100%
age '<=75' n 131 59% 31 48% 1 17% 163 56%
age '>75' n 91 41% 33 52% 5 83% 129 44%
gender 'female' n 109 49% 39 61% 4 67% 152 52%
gender 'male' n 113 51% 25 39% 2 33% 140 48%
managed care coverage 'yes' n 110 50% 33 52% 2 33% 145 50%
deceased 'yes' n 13 6% 4 6% 1 17% 18 6%
HSCT any time 'yes' n 54 24% 4 6% 0 0% 58 20%
HSCT in incidence year 'yes' n 36 16% 4 6% 0 0% 40 14%
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Table 3: Outpatient MM drug costs.  
Mean costs per MM drug regimen: Regimens are from any treatment line. The first day of drug regimen defines costing year. Analysis is based 
on 3061 observed patient years of prevalent MM patients from 2012 to 2017. From 2015 onwards, no valid cost data are available for complete 
treatment lines (light grey figures), as probably many treatment lines are not fully covered until end of observation period. 
Mean costs of MM drugs per day per patient (formula: average costs per regimen / average number of days under a regimen; watch and wait 
periods without MM drugs are not included herein). Valid cost data per day are available from 2012 to 2017. 
 
 
 
2012 2013 2014 2015 2016 2017
CHF CHF CHF CHF CHF CHF
Mean costs per MM drug regimen mean 95% - CI mean 95% - CI mean 95% - CI mean mean mean
all regimens 73764 137 to 397007 76368 85 to 374417 71060 187 to 313594 60297 274 to 238801 66103 1397 to 225936 34085 1475 to 98029
PI_based 74827 1411 to 342232 94914 3666 to 411318 74315 1741 to 324722 56673 1811 to 247540 68558 3686 to 225025 35508 1837 to 100327
IMID_based 85169 7440 to 447372 59227 6020 to 246112 76088 7128 to 302585 82800 6665 to 235718 65785 7001 to 236983 34384 5342 to 92911
CHEMO_based 528 52 to 3441 285 45 to 1289 1235 25 to 7382 270 49 to 588 400 50 to 1131 1049 57 to 3625
Mean costs of MM drugs per day per patient
all regimens 209 209 219 226 241 254
PI_based 202 213 214 217 229 235
IMID_based 243 212 239 257 273 282
CHEMO_based 3 3 21 3 16 13
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Table 4: Extrapolated annual outpatient MM drug costs of MM patients in Switzerland from 2012 to 2017. 
Extrapolation to Switzerland is based on 1054 prevalent Helsana MM patients from 2012 to 2017. Costs include only outpatient MM drugs as 
reimbursed by the Swiss Federal Law on Basic Health Insurance (BHI). Costs of inpatient treatment, of other drugs or of additional services are 
not included. MM drug costs are from any treatment line. Prescription date of each MM drug defines costing year. MM drugs are reported from 
2012 onwards or from the first year of reimbursement in Switzerland. Costs (CHF; per patient per year): calculated for each calendar year, 
irrespective of active MM treatment; thus, watch and wait periods without MM drugs are included herein. 
 
BHI: (Swiss) Basic Health Insurance; CHF: Swiss Francs; MM: multiple myeloma; pppy: per patient per year; Costs total OKP (CHF; pppy): include all-diagnoses inpatient and 
outpatient costs of myeloma patients, as reimbursed by health insurers based on the Swiss Federal Law on Basic Health Insurance (KVG/LAMal);  
mean 95% - CI mean 95% - CI mean 95% - CI mean 95% - CI mean 95% - CI mean 95% - CI
Lenaladomid (REVLIMID®) 41471 32606 to 50337 37017 30017 to 44018 34811 28252 to 41370 41751 33756 to 49746 59687 50184 to 69189 65570 55746 to 75393
Bortezomib (VELCADE®) 18630 15156 to 22105 21382 17709 to 25056 24627 20308 to 28946 26963 22714 to 31211 24397 19028 to 29766 22292 17426 to 27158
Pomalidomid (IMNOVID®) 3945 1751 to 6139 12581 7103 to 18060 11579 5825 to 17333 13369 6908 to 19830
Carfilzomib (KYPROLIS®) 123 30 to 287 7370 4360 to 10379 8372 4752 to 11992
Daratumumab (DARZALEX®) 6826 3355 to 10298
Ixazomib (NINLARO®) 1787 294 to 3279
Elotuzumab (EMPLICITI®) 31 7 to 94 402 56 to 955
Total 60101 58399 63383 81418 103064 118618
Estimated prevalence Switzerland (n) 1810 2360 3030 3410 3910 4200
Costs (CHF; per patient per year) 33205 24745 20918 23876 26359 28242
Costs total BHI (CHF; per pat per yr) 68374 56941 55161 54820 58101 57006
% costs MM-drugs of costs total BHI 0.49 0.43 0.38 0.44 0.45 0.50
2016 2017
thousand CHF thousand CHF thousand CHF thousand CHF thousand CHF thousand CHF
2012 2013 2014 2015
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Legends for figures: 
 
 
Figure 1: Study flow 
 
Figure 2: Treatment patterns. Sequence of treatment lines according to 1st-line 
drug regimen groups (PI-based: mean duration of 1st line: 218 days; IMID-based: 214 
days; CHEMO-based: 64 days). Analysis based on 292 of 378 incident MM patients 
from 2015 to 2017. 
 
Figure 3: Risk ratio for death and daily treatment costs under MM treatment 
compared to 2012. Analysis based on 3061 observed patient years of prevalent MM 
patients from 2012 to 2017. All risk ratios are calculated for reference year 2012. 
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Figure 1: Study flow 
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Figure 2: Treatment patterns. 
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Figure 3: Risk ratio for death and daily treatment costs under MM treatment 
compared to 2012. 
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Supplement: 
Figure S1: Inclusion procedure for prevalent and incident MM patients. Red lines are showing the trajectory of disease. Included persons 
had to be insured with Helsana for the whole calendar year. 
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Table S1: Applied grouping of MM drugs according to drug concepts into three MM drug regimens. 
 
 
 
Abbreviations (in alphabetical order): BENDA-Bendamustin; BOR-Bortezomib; DARA-Daratunumab; DEXA-Dexamethason; DOXO-
Doxorubicin; ELO-Elotuzumab; IXA-Ixazomib; LEN-Lenalidomid; MEL-Melphalan; POM-Pomalidomide; PRED-Prednisolon; THAL-Thalidomid; 
VIN – Vincristin 
  
drug concept regimen category example drug combination (within regimen)
Proteasoma Inhibitor PI-based BOR BOR +/- DEXA
BOR + IMID BOR - THAL
BOR - LEN
BOR + CHEMO BOR - MEL
BOR - Cyclophosphamid
BOR - liposomales DOXO (Caelyx®)
BOR - DOXO
BOR - BENDA
CAR + IMID CAR - LEN
IXA
Imide IMID-based THAL THAL - DEXA
LEN LEN - DEXA
POM POM - DEXA
LEN + CHEMO LEN - MEL
LEN - BENDA
LEN - Cyclophosphamid
POM + CHEMO POM - Cyclophophamid
THAL + CHEMO THAL - MEL
THAL - BENDA
Chemotherapy CHEMO-based BENDA BENDA - DEXA
MEL MEL - PRED
VIN VIN
Monoclonal antibodies MAB Daratunumab DARA - LEN- DEXA
Elotuzumab ELO - POM - DEXA
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Table S2: Duration of first line treatment and time to next treatment (TTNT) in 
days. Analysis based on 292 of 378 incident MM patients from 2015 to 2017. 
Duration of treatment: days between first and last medication of first line treatment. 
TTNT: interval between the last day of 1st treatment line and the first days of 2nd 
treatment line (or last day of observation period). 
 
Jahr 2015 Jahr 2016 Jahr 2017
total
group size n 119 90 83
duration of first line treatment mean (days) 221.8 275.2 135.5
time between treatments 1 and 2 mean (days) 355.7 259.3 189
time between treatments 1 and 2 
or end of observation mean (days) 359.9 184.7 41.3
Jahr 2015 Jahr 2016 Jahr 2017
PI-based
group size n 100 73 49
duration of first line treatment
total mean 209.8 298 146.6
age <= 75 mean 189.5 328.2 137.9
age > 75 mean 236.6 249.6 159.3
HSCT yes a) mean 145.2 309.9 161.2
HSCT no a) mean 232.4 294.4 142.4
HSCT yes b) mean 133.8 287.8 161.2
HSCT no b) mean 225.3 299.3 142.4
time between treatments 1 and 2 mean 351.2 283.4 189
time between treatments 1 and 2 or 
end of observation mean 358.2 185.5 43.2
IMID-based
group size n 16 15 33
duration of first line treatment
total mean 326.9 196.8 120.1
age <= 75 mean 328.3 187.8 143.5
age > 75 mean 325 210.3 105
HSCT yes a) mean - 109.3 133
HSCT no a) mean 326.9 218.7 119.7
HSCT yes b) mean - 109.3 133
HSCT no b) mean 326.9 218.7 119.7
time between treatments 1 and 2 mean 389 215.5 -
time between treatments 1 and 2 or 
end of observation mean 337.9 177.5 38.8
CHEMO-based
group size n 3 2 1
duration of first line treatment
total mean 61.3 30 100
age <= 75 mean 21 - -
age > 75 mean 81.5 30 100
HSCT yes a) mean - - -
HSCT no a) mean 61.3 30 100
HSCT yes b) mean - - -
HSCT no b) mean 61.3 30 100
time between treatments 1 and 2 mean 390 207 -
time between treatments 1 and 2 or 
end of observation mean 532 207 31
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Table S3: MM patients with hematopoietic stem cell transplantation (HSCT) according to year of HSCT. Analysis is based on 1054 
prevalent patients from 2012 to 2017. 
 
 
 
Jahr 2012 Jahr 2013 Jahr 2014 Jahr 2015 Jahr 2016 Jahr 2017
HSCT total n 21 26 23 35 29 31
HSCT autologuous n 20 24 23 34 29 31
age '<=75' n (%) 20 (100) 24 (100) 23 (100) 34 (100) 29 (100) 31 (100)
age '>75' n (%)  0 (  0)  0 (  0)  0 (  0)  0 (  0)  0 (  0)  0 (  0)
gender 'female' n (%) 10 (50)  7 (29.2) 14 (60.9) 14 (41.2) 16 (55.2) 17 (54.8)
gender 'male' n (%) 10 (50) 17 (70.8)  9 (39.1) 20 (58.8) 13 (44.8) 14 (45.2)
managed care coverage 'no' n (%)  7 (35) 11 (45.8) 13 (56.5) 15 (44.1) 14 (48.3) 10 (32.3)
managed care coverage 'yes' n (%) 13 (65) 13 (54.2) 10 (43.5) 19 (55.9) 15 (51.7) 21 (67.7)
all-diagnosis inpatient cost mean (median) 33'090 (29'931) 31'306 (27'840) 25'202 (19'372) 30'489 (26'321) 28'308 (27'222) 24'597 (22'997)
HSCT allogeneic n 1 2 0 1 0 0
